Chengdu Olymvax Biopharmaceuticals Inc Class A 688319
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥9.24
- Day Range
- ¥9.49–10.73
- 52-Week Range
- ¥7.06–22.88
- Bid/Ask
- ¥10.64 / ¥10.66
- Market Cap
- ¥4.32 Bil
- Volume/Avg
- 7.2 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 388.24
- Price/Sales
- 7.66
- Dividend Yield (Trailing)
- 0.41%
- Dividend Yield (Forward)
- 0.41%
- Total Yield
- 0.41%
Company Profile
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 471
- Website
- http://www.olymvax.com
Comparables
Valuation
|
Metric
|
688319
|
688278
|
688062
|
|---|---|---|---|
Price/Earnings (Normalized) | 388.24 | 37.92 | — |
Price/Book Value | 4.26 | 12.78 | 4.43 |
Price/Sales | 7.66 | 10.76 | 62.41 |
Price/Cash Flow | 482.20 | 34.36 | — |
Price/Earnings
688319
688278
688062
Financial Strength
|
Metric
|
688319
|
688278
|
688062
|
|---|---|---|---|
Quick Ratio | 1.63 | 3.14 | 1.53 |
Current Ratio | 1.83 | 4.07 | 1.78 |
Interest Coverage | −3.55 | 1,553.17 | −32.55 |
Quick Ratio
688319
688278
688062
Profitability
|
Metric
|
688319
|
688278
|
688062
|
|---|---|---|---|
Return on Assets (Normalized) | −3.07% | 30.63% | −24.26% |
Return on Equity (Normalized) | −5.38% | 37.49% | −41.90% |
Return on Invested Capital (Normalized) | −3.43% | 37.06% | −26.98% |
Return on Assets
688319
688278
688062
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pfrlrssbpz | Wjvcm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ncfvgvltc | Dtwqly | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mhdnxrk | Bflzck | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Brqwpvbg | Qwyfjx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Xzzkvwwvg | Xcpgg | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xbnntdvdm | Gtjl | $28.1 Bil | |||
| Moderna Inc
MRNA
| Nnbgjrqr | Xzcmf | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kjhdggf | Zwgg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Syzwslbry | Xvlkbf | $13.4 Bil | |||
| Incyte Corp
INCY
| Vmdchccy | Whxqyr | $12.7 Bil |
United States